

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
WO 01/21157 A2(51) International Patent Classification<sup>7</sup>: A61K 31/00TANGUAY, Jean-François [CA/CA]; C.P. 323, succ.  
Mont-Royal, Montreal, Quebec H3P 3C5 (CA).

(21) International Application Number: PCT/CA00/01132

(22) International Filing Date:  
21 September 2000 (21.09.2000)(74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc,  
The Stock Exchange Tower, Suite 3400, 800 Place Victoria,  
P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2,282,982 21 September 1999 (21.09.1999) CA  
2,300,246 9 March 2000 (09.03.2000) CA(71) Applicant (for all designated States except US): INSTI-  
TUT DE CARDIOLOGIE DE MONTREAL [CA/CA];  
5000 Bélanger Street East, Montreal, Quebec H1T 1C8  
(CA).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (for US only): CHAN-  
DRASEKAR, Baskaran [IN/IN]; 2, Justice Ramanujam  
Road, Dr. Radhakrishnan Nagar, Chennai 600 041 (IN).


Published:

— Without international search report and to be republished  
upon receipt of that report.


[Continued on next page]

(54) Title: LOCAL DELIVERY OF 17-BETA ESTRADIOL FOR PREVENTING VASCULAR INTIMA HYPERPLASIA AND  
FOR IMPROVING VASCULAR ENDOTHELIUM FUNCTION AFTER VASCULAR INJURY


A



C



B



D

(57) Abstract: The cardioprotective effects of estrogen are well recognized. In *in vitro* experiments, and upon systemic administration, 17-beta estradiol has shown to inhibit vascular smooth muscle cell proliferation and intima hyperplasia and to improve vascular endothelium function, after vascular injury. We hypothesized that locally delivered 17-beta estradiol could prevent restenosis. Compositions are use of 17-beta estradiol for *in-situ* administration at a vascular injured site are objects of the present invention.



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*